Tetracyclines: nonantibiotic properties and their clinical implications.

[1]  D. Jq.  A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines. , 2004 .

[2]  J. Leyden,et al.  Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. , 2003, Archives of dermatology.

[3]  V. Yong,et al.  Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. , 2002, Brain : a journal of neurology.

[4]  Betty Y. S. Kim,et al.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice , 2002, Nature.

[5]  L. Golub,et al.  Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non‐antimicrobial tetracycline analog (COL‐3) in a metastatic prostate cancer model , 2002, International journal of cancer.

[6]  N. Yokoyama,et al.  Modulation of oxidative burst of neutrophils by doxycycline in patients with acute myocardial infarction. , 2002, The Journal of antimicrobial chemotherapy.

[7]  F. Wojnarowska,et al.  Treatment of subepidermal immunobullous diseases. , 2001, Clinics in dermatology.

[8]  G. Chaidemenos.  Tetracycline and niacinamide in the treatment of blistering skin diseases. , 2001, Clinics in dermatology.

[9]  M. Leinonen,et al.  Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. , 2001, Journal of vascular surgery.

[10]  J. O'dell,et al.  Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. , 2001, Arthritis and rheumatism.

[11]  B. Baxter.  Regarding "Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study". , 2001, Journal of vascular surgery.

[12]  R. Kratzke,et al.  Inhibition of mesothelioma cell growth in vitro by doxycycline. , 2001, The Journal of laboratory and clinical medicine.

[13]  H. Newman,et al.  Utilisation of locally delivered doxycycline in non-surgical treatment of chronic periodontitis. A comparative multi-centre trial of 2 treatment approaches. , 2001, Journal of clinical periodontology.

[14]  G. Kirtschig,et al.  Minocycline as a therapeutic option in bullous pemphigoid , 2001, Clinical and experimental dermatology.

[15]  V. Ona,et al.  Minocycline Reduces Traumatic Brain Injury-mediated Caspase-1 Activation, Tissue Damage, and Neurological Dysfunction , 2001, Neurosurgery.

[16]  M. Hidalgo,et al.  Development of matrix metalloproteinase inhibitors in cancer therapy. , 2001, Journal of the National Cancer Institute.

[17]  S. Steinberg,et al.  Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Salo,et al.  The in vivo Expression of the Collagenolytic Matrix Metalloproteinases (MMP-2, -8, -13, and -14) and Matrilysin (MMP-7) in Adult and Localized Juvenile Periodontitis , 2000, Journal of dental research.

[19]  Y. Kawaoka,et al.  Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice , 2000, Nature Medicine.

[20]  M. Kaul,et al.  Functional role and therapeutic implications of neuronal caspase-1 and -3 in a mouse model of traumatic spinal cord injury , 2000, Neuroscience.

[21]  S. Hersch,et al.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.

[22]  P. Chan,et al.  A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Stieg,et al.  Reduction of post-traumatic brain injury and free radical production by inhibition of the caspase-1 cascade , 1999, Neuroscience.

[24]  Komai,et al.  Sublamina densa‐type linear IgA bullous dermatosis successfully treated with oral tetracycline and niacianamide , 1999, The British journal of dermatology.

[25]  B. Baxter,et al.  MMP Inhibition in Abdominal Aortic Aneurysms: Rationale for a Prospective Randomized Clinical Trial , 1999, Annals of the New York Academy of Sciences.

[26]  H. Hennies,et al.  Evidence for a single genetic locus in Clouston's hidrotic ectodermal dysplasia , 1999, The British journal of dermatology.

[27]  J. Westermarck,et al.  Regulation of matrix metalloproteinase expression in tumor invasion , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  T. Hökfelt,et al.  Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Jemec,et al.  Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. , 1998, Journal of the American Academy of Dermatology.

[30]  D. Trentham,et al.  Minocycline in early diffuse scleroderma , 1998, The Lancet.

[31]  W. Giannobile,et al.  Tetracyclines Inhibit Connective Tissue Breakdown by Multiple Non-Antimicrobial Mechanisms , 1998, Advances in dental research.

[32]  T. Salo,et al.  Inhibition of MMP Synthesis by Doxycycline and Chemically Modified Tetracyclines (CMTs) in Human Endothelial Cells , 1998, Advances in dental research.

[33]  S. Ciancio,et al.  Safety and Efficacy of Sub-Antimicrobial-Dose Doxycycline Therapy in Patients with Adult Periodontitis , 1998, Advances in dental research.

[34]  J. Barnes,et al.  Effect of Minocycline on Osteoporosis , 1998, Advances in dental research.

[35]  A. Vernillo,et al.  Effects of Tetracyclines on Bone Metabolism , 1998, Advances in dental research.

[36]  M. L. Nelson.  Chemical and Biological Dynamics of Tetracyclines , 1998, Advances in dental research.

[37]  T. Salo,et al.  Matrix Metalloproteinase-8 Is Expressed in Rheumatoid Synovial Fibroblasts and Endothelial Cells , 1997, The Journal of Biological Chemistry.

[38]  C. Lowenstein,et al.  Post‐transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines , 1997, FEBS letters.

[39]  D. Fivenson,et al.  Lichen planus pemphigoides: combination therapy with tetracycline and nicotinamide. , 1997, Journal of the American Academy of Dermatology.

[40]  M. Moskowitz,et al.  Expression of a Dominant Negative Mutant of Interleukin-1β Converting Enzyme in Transgenic Mice Prevents Neuronal Cell Death Induced by Trophic Factor Withdrawal and Ischemic Brain Injury , 1997, The Journal of experimental medicine.

[41]  G. Plewig,et al.  Rosacea: Classification and Treatment , 1997, Journal of the Royal Society of Medicine.

[42]  S. Abramson,et al.  A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  L. Golub,et al.  Potential of tetracyclines to modify cartilage breakdown in osteoarthritis. , 1996, Current opinion in rheumatology.

[44]  L. Shapira,et al.  Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion , 1996, Infection and immunity.

[45]  F. Breedveld,et al.  The effect of minocycline in rat models of inflammatory arthritis: correlation of arthritis suppression with enhanced T cell calcium flux. , 1996, Cellular immunology.

[46]  F. Breedveld,et al.  The influence of tetracyclines on T cell activation , 1995, Clinical and experimental immunology.

[47]  J. Remme,et al.  Bullous pemphigoid successfully controlled by tetracycline and nicotinamide , 1995, The British journal of dermatology.

[48]  F. Wojnarowska,et al.  Minimizing cicatricial pemphigoid orodynia with minocycline , 1995, The British journal of dermatology.

[49]  S. Pillemer,et al.  Minocycline in Rheumatoid Arthritis: A 48-Week, Double-Blind, Placebo-Controlled Trial , 1995, Annals of Internal Medicine.

[50]  G. Webster,et al.  Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. , 1994, Archives of dermatology.

[51]  D. Fivenson,et al.  Nicotinamide and tetracycline therapy of bullous pemphigoid. , 1994, Archives of dermatology.

[52]  B. Dijkmans,et al.  Minocycline in Active Rheumatoid Arthritis , 1994 .

[53]  J. Wilkin.  Rosacea. Pathophysiology and treatment. , 1994, Archives of dermatology.

[54]  L. Liotta,et al.  Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  D. Fivenson,et al.  Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. , 1993, Journal of the American Academy of Dermatology.

[56]  D. Atukorala,et al.  Successful treatment of Sweet's syndrome with doxycycline , 1993, The British journal of dermatology.

[57]  Ph. D. Albert M. Kligman M.D.,et al.  ACNE and ROSACEA , 1992, Springer Berlin Heidelberg.

[58]  D. A. Brandt,et al.  Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. , 1992, Arthritis and rheumatism.

[59]  P. Vadas,et al.  Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. , 1992, Biochemical pharmacology.

[60]  D. Fivenson,et al.  Linear IgA bullous dermatosis: successful treatment with tetracycline and nicotinamide. , 1992, Journal of the American Academy of Dermatology.

[61]  L. Golub,et al.  Host modulation with tetracyclines and their chemically modified analogues. , 1992, Current opinion in dentistry.

[62]  R. Tamargo,et al.  Angiogenesis inhibition by minocycline. , 1991, Cancer research.

[63]  P. Agache,et al.  Use of anti-collagenase properties of doxycycline in treatment of alpha 1-antitrypsin deficiency panniculitis. , 1991, Acta dermato-venereologica.

[64]  S. Feldman,et al.  The effect of doxycycline on ocular rosacea. , 1989, American journal of ophthalmology.

[65]  A. Lorincz,et al.  The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. , 1986, Archives of dermatology.

[66]  L. Golub,et al.  Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease. , 1984 .

[67]  N. Esterly,et al.  Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy. , 1984, Archives of dermatology.

[68]  H. M. Lee,et al.  Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. , 1983, Journal of periodontal research.

[69]  J. White,et al.  Characterization of chlortetracycline (aureomycin) as a calcium ionophore. , 1982, Biochemistry.

[70]  A. Ferrante,et al.  Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues. , 1979, Clinical and experimental immunology.

[71]  G. Plewig,et al.  Anti-inflammatory effects of antimicrobial agents: an in vivo study. , 1975, The Journal of investigative dermatology.

[72]  T. Piamphongsant.  Tetracycline for the treatment of pityriasis lichenoides , 1974, The British journal of dermatology.

[73]  R. Couch,et al.  Effects of tetracycline on leukotaxis. , 1974, The Journal of infectious diseases.

[74]  M. Feiwel,et al.  PERIORAL DERMATITIS: AETIOLOGY AND TREATMENT WITH TETRACYCLINE , 1972, The British journal of dermatology.

[75]  R. Woodward,et al.  The Structure of Aureomycin1 , 1954 .

[76]  J. D. Del Rosso.  A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines. , 2004, Cutis.

[77]  H. M. Lee,et al.  Inhibition of proteolytic, serpinolytic, and progelatinase-b activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives. , 2002, Journal of periodontology.

[78]  D. Scadden,et al.  Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  L. Dubertret,et al.  The use of tetracyclines for the treatment of sarcoidosis. , 2001, Archives of dermatology.

[80]  H. Hirte,et al.  Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. , 1997, Invasion & metastasis.

[81]  A. Peserico,et al.  Minocycline in granulomatous cheilitis: experience with 6 cases. , 1992, Dermatology.

[82]  L. Golub,et al.  Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. , 1991, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[83]  M. Vignon-Pennamen,et al.  Cutaneous Manifestations of Neutrophilic Disease , 1991 .

[84]  A. Finlay,et al.  How orally administered terbinafine reaches the stratum corneum , 1990 .

[85]  A. Pembroke,et al.  The successful use of minocycline in pyoderma gangrenosum—a report of seven cases and review of the literature , 1989 .

[86]  H. Sigel.  Antibiotics and their complexes , 1985 .

[87]  N. Esterly,et al.  The effect of antimicrobial agents on leukocyte chemotaxis. , 1978, The Journal of investigative dermatology.